Q3 EPS Estimate for Lexeo Therapeutics Raised by Analyst

Key Points

• Leerink Partners has raised their Q3 2025 EPS estimate for Lexeo Therapeutics from ($0.65) to ($0.64), indicating a slight improvement.
• Multiple brokerages have issued positive ratings and increased target prices for Lexeo Therapeutics, with Chardan Capital raising its target price from $15.00 to $17.00.
• Lexeo Therapeutics has recently attracted significant institutional investment, with hedge funds owning approximately 60.67% of the company's stock.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a note issued to investors on Tuesday, October 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.64) for the quarter, up from their prior forecast of ($0.65). The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics' Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($2.32) EPS and FY2027 earnings at ($2.56) EPS.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.04.

Several other brokerages have also recently issued reports on LXEO. Chardan Capital lifted their target price on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday. Oppenheimer started coverage on shares of Lexeo Therapeutics in a research note on Thursday, July 31st. They set an "outperform" rating and a $20.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexeo Therapeutics in a research note on Wednesday. Leerink Partners lifted their target price on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, HC Wainwright lifted their target price on shares of Lexeo Therapeutics from $9.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $17.00.

Lexeo Therapeutics Price Performance

Shares of NASDAQ:LXEO opened at $8.20 on Friday. The business's 50 day moving average price is $5.42 and its 200-day moving average price is $4.19. The firm has a market capitalization of $442.81 million, a price-to-earnings ratio of -2.52 and a beta of 1.66. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $11.72.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Balyasny Asset Management L.P. purchased a new stake in Lexeo Therapeutics in the 2nd quarter valued at about $16,117,000. Frazier Life Sciences Management L.P. raised its holdings in Lexeo Therapeutics by 363.1% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company's stock valued at $17,787,000 after buying an additional 3,469,210 shares during the period. Affinity Asset Advisors LLC raised its holdings in Lexeo Therapeutics by 142.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 3,589,355 shares of the company's stock valued at $14,429,000 after buying an additional 2,108,474 shares during the period. Vestal Point Capital LP raised its holdings in Lexeo Therapeutics by 184.1% in the 2nd quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company's stock valued at $12,977,000 after buying an additional 2,091,912 shares during the period. Finally, Millennium Management LLC raised its holdings in Lexeo Therapeutics by 654.8% in the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock valued at $3,718,000 after buying an additional 929,538 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.